Celltrion Obtains Domestic Approval from MFDS for Humira Biosimilar 'Yuflyma'
[Asia Economy Reporter Gong Byung-sun] Celltrion announced on the 15th that its biosimilar 'Yuflyma,' developed as the first high-concentration formulation biosimilar of Humira by removing citrate, has obtained domestic product approval from the Ministry of Food and Drug Safety.
Specifically, Yuflyma is indicated for adult rheumatoid arthritis, ankylosing spondylitis, adult Crohn's disease, psoriasis, as well as pediatric Crohn's disease, juvenile idiopathic arthritis, and pediatric plaque psoriasis.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Going forward, Celltrion stated that based on the secured clinical data, it plans to apply for approvals in each country through continuous discussions with global regulatory agencies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
